Bozkurt, E.Atay, E.Pektas, G.Ertekin, A.Vurmaz, A.Korkmaz, Ö.A.Sadi, G.2024-09-292024-09-2920201735-0328https://doi.org/10.22037/ijpr.2020.112993.14060https://hdl.handle.net/20.500.14619/9065We investigated the potential influence of kefir-induced juglone and resveratrol fractions (JRK) against Ehrlich Ascites Carcinoma (EAC) bearing BALB/c male mice. Kefir yeast was grown in the cell culture supplemented with juglone and resveratrol (1:2). After 48 h incubation, JRK solution was applied (0.1 mL/day i.p.) to the EAC-bearing mice throughout five days. Molecular regulatory mechanisms of apoptotic and anti-apoptotic pathway components were evaluated in the plasma of mice and isolated EAC cells with ELISA, qRT-PCR, and immunocytchemical experiments. EAC-induced upregulation in Bcl-2 and downregulation in Caspase-3 were normalized with JRK in the plasma of mice. Additionally, JRK upregulated the expression levels of apoptotic Bax, p53, Caspase-3,8,9, and APAF-1 proteins together with BAX, CASPASE-8, and CASPASE-9 genes in isolated EAC cells. These changes were also associated with decreased expression levels of anti-apoptotic Bcl-2 and Bcl-xl proteins. Immunocytochemical studies also confirmed the activation of apoptotic pathways and repression of anti-apoptotic proteins in EAC cells with JRK treatment. JRK activates apoptotic pathway and inhibits anti-apoptotic genes and proteins in Ehrlich ascites carcinoma-bearing BALB/c mice that could be beneficial in cancer treatment. © 2020, Iranian Journal of Pharmaceutical Research. All rights reserved.eninfo:eu-repo/semantics/closedAccessBaxBcl-2CaspaseEhrlich ascitesJugloneKefirP53ResveratrolArticle10.22037/ijpr.2020.112993.140602-s2.0-850976576903693Q235819